Samsung Biologics announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at the company's latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
777,000 KRW | -0.26% | -0.51% | +2.24% |
07:14am | US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz | MT |
05-06 | Samsung Group Firms Set to Invest in US-based Latus Bio | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.24% | 40.49B | |
-1.62% | 89.22B | |
-14.97% | 32.79B | |
+64.13% | 26.23B | |
-21.82% | 14.52B | |
-7.64% | 13.09B | |
-42.60% | 11.6B | |
-12.64% | 11.5B | |
+4.94% | 8.82B | |
-13.45% | 7.92B |
- Stock Market
- Equities
- A207940 Stock
- News Samsung Biologics Co.,Ltd.
- Samsung Biologics Co., Ltd. Announces Expanded Strategic Agreement with Bristol Myers Squibb to Manufacture an Antibody Cancer Drug Substance